AAV vector vs. Lentiviral vectors for gene therapy

Scroll Down

Viral vectors are effective and efficient tools for gene therapy, transducing and delivering genes to target cell populations and achieving sustainable expression. The efficacy of a gene therapy is heavily dependent on the delivery vehicle chosen.

The most popular vectors for gene therapy are derived from adeno-associated viral vectors (AAV vectors) and lentiviral vectors. Both vectors can induce gene expression and cause limited immune response in the host.

AAV and lentiviral vector platforms offer their own unique pros and cons that could influence the viability and success of the gene therapy program chosen. With extensive expertise, Genezen understands the importance of making the right viral vector choice.

For insight into which viral vector could be best suited for your next gene therapy project, download our AAV vs. LV vector comparative overview by completing the form to the right.

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more